在急性髓性白血病中T细胞参与者:分子标,结构和治疗挑战
Hunter Daws1,2, Kate Gallinero1,2, Amanda Singh1
1Vanadro Drug Development Consulting, West Des Moines, IA 50266, USA.
Cancers
|October 16, 2025
概括
通过引导免疫细胞向癌症,T细胞参与剂 (TCE) 显示出治疗急性髓性白血病 (AML) 的前景. 然而,抗原选择和毒性方面的挑战阻碍了临床进展.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 血液学 血液学 血液学
背景情况:
- 由于复发率高,急性髓性白血病 (AML) 治疗面临挑战.
- T细胞参与剂 (TCEs) 代表了AML的新型免疫治疗策略.
- 通过结合CD3和瘤抗原,TCEs将T细胞重定向到AML细胞的点.
研究的目的:
- 审查目前用于AML治疗的TCEs的发展情况.
- 要突出主要的AML抗原和正在调查中的TCE格式.
- 讨论基于TCE的AML治疗中的挑战和机遇.
主要方法:
- 对AML中TCEs的临床前和临床研究的综述.
- 对各种TCE格式 (BiTE,DuoBodies,DART,DARPin) 的分析.
- 对常见和新出现的AML基抗原的评估 (CD33,CD123,CD135,CD38,CLEC12A/CLL-1).
主要成果:
- CD33和CD123是主要的目标,其他正在调查中.
- 目前正在开发各种TCE格式,以提高疗效和药理动力学.
- 由于抗原限制和毒性问题,如细胞因子释放综合征 (CRS),没有任何TCE超出早期阶段 (I/II) 试验.
结论:
- TCEs对于AML具有显著的治疗潜力.
- 优化抗原选择和管理与免疫相关的毒性对临床成功至关重要.
- 需要进一步的研究来将TCE推进到AML的后期临床试验中.
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.9K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.9K